Research programme: phosphatidylinositol 3-kinase inhibitors - Roche
Alternative Names: PI 509; PI 516; PI-540; PI-620; RO2492Latest Information Update: 04 Nov 2017
At a glance
- Originator Astellas Pharma; Cancer Research UK; Ludwig Institute for Cancer Research; The Institute of Cancer Research
- Developer Roche
- Class Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haematological malignancies; Rheumatoid arthritis
- Discontinued Viral infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Haematological-malignancies in United Kingdom (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in United Kingdom (Parenteral)
- 07 Mar 2011 Preclinical development is ongoing in United Kingdom